Research ArticleOpen AccessGoogle Scholar indexed
Biological Therapy in IBD—Is There Any Optimal End Point?
First Department of Medicine, University of Szeged, Szeged, Hungary
First Department of Medicine, University of Szeged, Szeged, Hungary
- 1 First Department of Medicine, University of Szeged, Szeged, Hungary
- 2 First Department of Medicine, University of Szeged, Szeged, Hungary
Copy link · social · email
Abstract
Biological therapy has been used in the treatment of inflammatory bowel disease (IBD-Crohn’s disease [CD], ulcerative colitis [UC]) for more than a decade. Although guidelines exist on how to start and adjust biological therapy, information on when and how it should be stopped is still scarce. In this review, our aim is to summarize the results of the recently published papers on the outcome of the discontinuation of biological therapy in patients with CD and UC.
KeywordsCrohn’s DiseaseUlcerative ColitisBiological TherapyDiscontinuation
- Schnitzler, F., Fidder, H., Ferrante, M., Schnitzler, F., Fidder, H., Ferrante, M., Noman, M., Arijs, I., Van Assche, G., Hoffman, I., Van Steen, K., Vermeire, S. and Rutgeerts, P. (2009) Long-Term Outcome of Treatment with Infliximab in 614 Patients with Crohn’s Disease: Results from a Single-Centre Cohort. Gut, 58, 492-500. http://dx.doi.org/10.1136/gut.2008.155812
- Waugh, A.W., Garg, S., Matic, K., Gramlich, L., Wong, C., Sadowski, D.C., Millan, M., Bailey, R., Todoruk, D., Cherry, R., Teshima, C.W., Dieleman, L. and Fedorak, R.N. (2010) Maintenance of Clinical Benefit in Crohn’s Disease Patients after Discontinuation of Infliximab: Long-Term Follow-Up of a Single Centre Cohort. Alimentary Pharmacology & Therapeutics, 32, 1129-1134. http://dx.doi.org/10.1111/j.1365-2036.2010.04446.x
- D’Haens, G.R., Panaccione, R., Higgins, P.D., Vermeire, S., Gassull, M., Chowers, Y., Hanauer, S.B., Herfarth, H., Hommes, D.W., Kamm, M., Löfberg, R., Quary, A., Sands, B., Sood, A., Watermeyer, G., Lashner, B., Lémann, M., Plevy, S., Reinisch, W., Schreiber, S., Siegel, C., Targan, S., Watanabe, M., Feagan, B., Sandborn, W.J., Colombel, J.F. and Travis, S. (2011) The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? The American Journal of Gastroenterology, 106, 199-212. http://dx.doi.org/10.1038/ajg.2010.392
- Louis, E., Mary, J.Y., Vernier-Massouille, G., Grimaud, J.C., Bouhnik, Y., Laharie, D., Dupas, J.L., Pillant, H., Picon, L., Veyrac, M., Flamant, M., Savoye, G., Jian, R., Devos, M., Porcher, R., Paintaud, G., Piver, E., Colombel, J.F., Lemann, M. and Groupe D’etudes Thérapeutiques Des Affections Inflammatoires Digestives (2012) Maintenance of Remission among Patients with Crohn’s Disease on Antimetabolite Therapy after Infliximab Therapy Is Stopped. Gastroenterology, 1, 63-70. http://dx.doi.org/10.1053/j.gastro.2011.09.034
- Steenholdt, C., Molazahi, A., Ainrworth, M.A., Brynskov, J., Østergaard Thomsen, O. and Seidelin, J.B. (2012) Outcome after Discontinuation of Infliximab in Patients with Inflammatory Bowel Disease in Clinical Remission: An Observational Danish Single Center Study. Scandinavian Journal of Gastroenterology, 47, 518-527. http://dx.doi.org/10.3109/00365521.2012.660541
- Armuzzi, A., Marzo, M., Felice, C., et al. (2010) Long-Term Scheduled Therapy with Infliximabin Inflammatory Bowel Disease: A Single-Centre Observational Study. Gastroenterology, 5, S691-692.